Cytori Therapeutics Inc. (NASDAQ:CYTX)’s share price shot up 3.9% during trading on Friday . The company traded as high as $2.16 and last traded at $2.13, with a volume of 318,286 shares trading hands. The stock had previously closed at $2.05.

A number of research firms have recently commented on CYTX. Zacks Investment Research lowered shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Roth Capital reissued a “buy” rating and issued a $11.00 price target on shares of Cytori Therapeutics in a research report on Tuesday, June 28th. Finally, Maxim Group reissued a “buy” rating on shares of Cytori Therapeutics in a research report on Monday, June 27th.

The stock has a 50-day moving average price of $2.05 and a 200 day moving average price of $2.82. The company’s market cap is $28.93 million.

Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Tuesday, May 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.38. The company earned $2.90 million during the quarter, compared to analyst estimates of $2.05 million. During the same period last year, the firm posted ($0.07) earnings per share. The business’s quarterly revenue was up 26.1% compared to the same quarter last year. On average, equities research analysts expect that Cytori Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.